Affinity Asset Advisors’s Apogee Therapeutics APGE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-987,000
Closed -$131M – 123
2026
Q2
$131M Sell
987,000
-297,926
-23% -$26.8M 5.92% 2
2026
Q1
$108M Buy
1,284,926
+50,000
+4% +$3.63M 5.59% 2
2025
Q4
$93.2M Buy
1,234,926
+61,500
+5% +$3.87M 5.31% 2
2025
Q3
$46.6M Buy
1,173,426
+481,527
+70% +$18.4M 4.06% 6
2025
Q2
$30M Sell
691,899
-459,300
-40% -$17.5M 4.1% 7
2025
Q1
$43M Buy
1,151,199
+219,471
+24% +$8.49M 4.1% 4
2024
Q4
$42.2M Buy
931,728
+267,530
+40% +$13.6M 5.66% 3
2024
Q3
$39M Sell
664,198
-172,085
-21% -$8.25M 5.32% 3
2024
Q2
$32.9M Buy
836,283
+244,190
+41% +$11.9M 3.79% 3
2024
Q1
$39.3M Buy
592,093
+55,000
+10% +$2.4M 4.87% 3
2023
Q4
$15M Sell
537,093
-508,017
-49% -$10.2M 2.74% 12
2023
Q3
$22.3M Buy
+1,045,110
New +$23M 6.26% 1

Other funds holding APGE

Affinity Asset Advisors's APGE Position: Q3 2026 in Review

Affinity Asset Advisors sold out of Apogee Therapeutics (APGE) in Q3 2026, closing a stake of 987,000 shares — an estimated $131M sold.

Affinity Asset Advisors first reported a position in APGE in Q3 2023 and held it in 12 quarters. The position peaked at $131M in Q2 2026. 2 funds tracked by Wall St. Rank hold APGE as of Q3 2026.

  • Affinity Asset Advisors reported no remaining Apogee Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Affinity Asset Advisors sold 987,000 Apogee Therapeutics shares in Q3 2026, an estimated $131M.
  • Affinity Asset Advisors first reported a position in Apogee Therapeutics in Q3 2023 and held it in 12 quarters.
  • Affinity Asset Advisors's Apogee Therapeutics position peaked at $131M in Q2 2026.
  • 2 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q3 2026.

Based on Affinity Asset Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.